HA-MAD1 tumors have increased CIN and decreased p53. by Sarah E. Copeland (13951506)

Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

Comparison of (a) Chao index and (b) Shannon diversity index of the fecal microbiota in WT and Lep KO mice. by Yu Sang Choi (22656230)

Bar graphs showing the means and 95% CI of each retinal layer thickness at each visit. by Jung-Tae Kim (8997767)

Subjects:

Parafoveal thickness in each retinal layer at each visit. by Jung-Tae Kim (8997767)

Subjects:

Rates of change in each retinal layer thickness, calculated using linear mixed models. by Jung-Tae Kim (8997767)

Subjects:

Linear mixed-effect model determination of factors associated with changes in best-corrected visual acuity. by Jung-Tae Kim (8997767)

Subjects:

This file contains the complete dataset analyzed in the current study, including all variables used for statistical modeling. by Jung-Tae Kim (8997767)

Subjects:

Aβ and vGlut2 staining of 6-, 9-, and 12-month dLGN sections show significant plaque load and accelerated loss of retinal ganglion cell axon terminals in the 5xFAD mice. by Shaylah McCool (20818280)

Data Sheet 1_Irrigation, variety, and year exert a greater influence on organic potato production than microbial inoculation: case study results of a 2-year on-farm experiment.docx by Orsolya Papp (18206269)

“…Concerning the effects of microbial inoculations, significant differences were observed only in plant stomatal conductance among all measured parameters: inoculation with T. asperelloides significantly decreased stomatal conductance in potato plants. …”

Decreased clonogenic capacity of U87MG and U251MG GB cells following treatment with SHG-44 and cis-platin at equal concentrations. by Denis Mustafov (19137870)

“…<p><b>(A)</b> A significant reduction in colony-forming ability was observed in U87MG cells treated with 100ΜM SHG-44 compared to 100ΜM cis-platin and the untreated control. …”

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

The characteristics and clinical features of 12 patients. by Masashi Okawa (8951294)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects:

Equation of the equilibrium dissociation constant of the antigen-antibody reaction. by Masashi Okawa (8951294)

Subjects:

The original data for the figures. by Masashi Okawa (8951294)

Subjects:

Blood concentrations of VEGF-A121, VEGF-A165, and VEGF-A pre- and post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects:

VEGF-A121, VEGF-A165, and VEGF-A contents per unit platelets. by Masashi Okawa (8951294)

Subjects:

Hypothetical mechanism by which plasma VEGF-A121 concentration is elevated post-bevacizumab administration. by Masashi Okawa (8951294)

Subjects: